龙沙集团确定2026年普通股东大会召开日期 - TipRanks
Lonza Sets Date for 2026 Ordinary General Meeting - TipRanks
生物技术与制药领域的最新动态
Lonza Sets Date for 2026 Ordinary General Meeting - TipRanks
Lonza’s Capsules Sale Talks Are Nearing The Finish Line - Finimize
Narrow-Moat Lonza's Long-Term Outlook Driven by Strong Outsourced Drug Manufacturing Demand - Morningstar
Lonza still intends to sell its capsules and health ingredients business - Endpoints News
Earnings call transcript: Lonza reports strong 2025 results, stock dips - Investing.com
Lonza Sees Steady 2026 Growth After A Strong 2025 - Finimize
Switzerland's Lonza edges closer to sale of its capsule and health ingredients business - Reuters
Lonza delivers strong profitable growth in 2025 - The Pharma Letter
Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - Reuters
Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - wkzo.com
Lonza forecasts 2026 sales growth of 11-12% for core CDMO business - MSN
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza forecasts 2026 sales growth of 11-12% for core CDMO business - Global Banking & Finance Review
Lonza Delivers Strong Profitable Growth in Full-Year 2025 and Successfully Completes Vacaville Site Integration - TradingView
Lonza Group AG (LONN.SW, SIX): CHF550.20 intraday ahead of 28 Jan earnings — what to watch - Meyka